BlackRock, Inc. 13D and 13G filings for Sage Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Sage Therapeutics, Inc. SAGE | BlackRock Inc. BLK | 5,390,913 8.800% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | Sage Therapeutics, Inc. SAGE | BlackRock Inc. BLK | 5,390,913 8.800% | 727,013 (+15.59%) | Filing |
| 2024-01-26 11:49 am Sale | 2023-12-31 | 13G | Sage Therapeutics, Inc. SAGE | BlackRock Inc. BLK | 4,663,900 7.800% | -246,242 (-5.01%) | Filing |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | Sage Therapeutics, Inc. SAGE | BlackRock Inc. BLK | 4,910,142 8.300% | 1,999,872 (+68.72%) | Filing |
| 2021-01-08 4:37 pm Purchase | 2020-12-31 | 13G | Sage Therapeutics, Inc. SAGE | BlackRock Inc. BLK | 2,910,270 4.990% | 125,022 (+4.49%) | Filing |